Publication

Dry powder inhalation: past, present and future

de Boer, A., Hagedoorn, P., Hoppentocht, M., Buttini, F., Grasmeijer, F. & Frijlink, H. W., Apr-2017, In : Expert Opinion on Drug Delivery. 14, 4, p. 499-512 14 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

de Boer, A., Hagedoorn, P., Hoppentocht, M., Buttini, F., Grasmeijer, F., & Frijlink, H. W. (2017). Dry powder inhalation: past, present and future. Expert Opinion on Drug Delivery, 14(4), 499-512. https://doi.org/10.1080/17425247.2016.1224846

Author

de Boer, Anne ; Hagedoorn, P. ; Hoppentocht, M. ; Buttini, F ; Grasmeijer, F. ; Frijlink, H.W. / Dry powder inhalation : past, present and future. In: Expert Opinion on Drug Delivery. 2017 ; Vol. 14, No. 4. pp. 499-512.

Harvard

de Boer, A, Hagedoorn, P, Hoppentocht, M, Buttini, F, Grasmeijer, F & Frijlink, HW 2017, 'Dry powder inhalation: past, present and future', Expert Opinion on Drug Delivery, vol. 14, no. 4, pp. 499-512. https://doi.org/10.1080/17425247.2016.1224846

Standard

Dry powder inhalation : past, present and future. / de Boer, Anne; Hagedoorn, P.; Hoppentocht, M.; Buttini, F; Grasmeijer, F.; Frijlink, H.W.

In: Expert Opinion on Drug Delivery, Vol. 14, No. 4, 04.2017, p. 499-512.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

de Boer A, Hagedoorn P, Hoppentocht M, Buttini F, Grasmeijer F, Frijlink HW. Dry powder inhalation: past, present and future. Expert Opinion on Drug Delivery. 2017 Apr;14(4):499-512. https://doi.org/10.1080/17425247.2016.1224846


BibTeX

@article{43bd904825754f4997e0d2deacbfeb13,
title = "Dry powder inhalation: past, present and future",
abstract = "INTRODUCTION: Early dry powder inhalers (DPIs) were designed for low drug doses in asthma and COPD therapy. Nearly all concepts contained carrier-based formulations and lacked efficient dispersion principles. Therefore, particle engineering and powder processing are increasingly applied to achieve acceptable lung deposition with these poorly designed inhalers.AREAS COVERED: The consequences of the choices made for early DPI development with respect of efficacy, production costs and safety and the tremendous amount of energy put into understanding and controlling the dispersion performance of adhesive mixtures are discussed. Also newly developed particle manufacturing and powder formulation processes are presented as well as the challenges, objectives, and new tools available for future DPI design.EXPERT OPINION: Improved inhaler design is desired to make DPIs for future applications cost-effective and safe. With an increasing interest in high dose drug delivery, vaccination and systemic delivery via the lungs, innovative formulation technologies alone may not be sufficient. Safety is served by increasing patient adherence to the therapy, minimizing the use of unnecessary excipients and designing simple and self-intuitive inhalers, which give good feedback to the patient about the inhalation maneuver. For some applications, like vaccination and delivery of hygroscopic formulations, disposable inhalers may be preferred.",
keywords = "Adhesive mixtures, dry powder inhaler design, drug formulation, drug deposition, inhalation, particle engineering, COMPUTATIONAL FLUID-DYNAMICS, AIR CLASSIFIER TECHNOLOGY, PULMONARY DRUG-DELIVERY, METERED-DOSE INHALER, SPRAY-DRIED POWDERS, EXCIPIENT ENHANCED GROWTH, LUNG DEPOSITION, AEROSOL DEPOSITION, GAMMA-SCINTIGRAPHY, PARTICLE-SIZE",
author = "{de Boer}, Anne and P. Hagedoorn and M. Hoppentocht and F Buttini and F. Grasmeijer and H.W. Frijlink",
year = "2017",
month = "4",
doi = "10.1080/17425247.2016.1224846",
language = "English",
volume = "14",
pages = "499--512",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Taylor and Francis Ltd",
number = "4",

}

RIS

TY - JOUR

T1 - Dry powder inhalation

T2 - past, present and future

AU - de Boer, Anne

AU - Hagedoorn, P.

AU - Hoppentocht, M.

AU - Buttini, F

AU - Grasmeijer, F.

AU - Frijlink, H.W.

PY - 2017/4

Y1 - 2017/4

N2 - INTRODUCTION: Early dry powder inhalers (DPIs) were designed for low drug doses in asthma and COPD therapy. Nearly all concepts contained carrier-based formulations and lacked efficient dispersion principles. Therefore, particle engineering and powder processing are increasingly applied to achieve acceptable lung deposition with these poorly designed inhalers.AREAS COVERED: The consequences of the choices made for early DPI development with respect of efficacy, production costs and safety and the tremendous amount of energy put into understanding and controlling the dispersion performance of adhesive mixtures are discussed. Also newly developed particle manufacturing and powder formulation processes are presented as well as the challenges, objectives, and new tools available for future DPI design.EXPERT OPINION: Improved inhaler design is desired to make DPIs for future applications cost-effective and safe. With an increasing interest in high dose drug delivery, vaccination and systemic delivery via the lungs, innovative formulation technologies alone may not be sufficient. Safety is served by increasing patient adherence to the therapy, minimizing the use of unnecessary excipients and designing simple and self-intuitive inhalers, which give good feedback to the patient about the inhalation maneuver. For some applications, like vaccination and delivery of hygroscopic formulations, disposable inhalers may be preferred.

AB - INTRODUCTION: Early dry powder inhalers (DPIs) were designed for low drug doses in asthma and COPD therapy. Nearly all concepts contained carrier-based formulations and lacked efficient dispersion principles. Therefore, particle engineering and powder processing are increasingly applied to achieve acceptable lung deposition with these poorly designed inhalers.AREAS COVERED: The consequences of the choices made for early DPI development with respect of efficacy, production costs and safety and the tremendous amount of energy put into understanding and controlling the dispersion performance of adhesive mixtures are discussed. Also newly developed particle manufacturing and powder formulation processes are presented as well as the challenges, objectives, and new tools available for future DPI design.EXPERT OPINION: Improved inhaler design is desired to make DPIs for future applications cost-effective and safe. With an increasing interest in high dose drug delivery, vaccination and systemic delivery via the lungs, innovative formulation technologies alone may not be sufficient. Safety is served by increasing patient adherence to the therapy, minimizing the use of unnecessary excipients and designing simple and self-intuitive inhalers, which give good feedback to the patient about the inhalation maneuver. For some applications, like vaccination and delivery of hygroscopic formulations, disposable inhalers may be preferred.

KW - Adhesive mixtures

KW - dry powder inhaler design

KW - drug formulation

KW - drug deposition

KW - inhalation

KW - particle engineering

KW - COMPUTATIONAL FLUID-DYNAMICS

KW - AIR CLASSIFIER TECHNOLOGY

KW - PULMONARY DRUG-DELIVERY

KW - METERED-DOSE INHALER

KW - SPRAY-DRIED POWDERS

KW - EXCIPIENT ENHANCED GROWTH

KW - LUNG DEPOSITION

KW - AEROSOL DEPOSITION

KW - GAMMA-SCINTIGRAPHY

KW - PARTICLE-SIZE

U2 - 10.1080/17425247.2016.1224846

DO - 10.1080/17425247.2016.1224846

M3 - Article

VL - 14

SP - 499

EP - 512

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 4

ER -

ID: 35432868